A detailed history of Pnc Financial Services Group, Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 47,707 shares of AVXL stock, worth $355,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,707
Previous 39,307 21.37%
Holding current value
$355,417
Previous $165,000 63.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$4.11 - $7.04 $34,524 - $59,136
8,400 Added 21.37%
47,707 $270,000
Q2 2024

Aug 09, 2024

BUY
$3.39 - $5.02 $55,436 - $82,092
16,353 Added 71.24%
39,307 $165,000
Q1 2024

May 10, 2024

BUY
$4.55 - $6.75 $23,760 - $35,248
5,222 Added 29.45%
22,954 $116,000
Q4 2023

Feb 09, 2024

BUY
$5.04 - $9.95 $1,411 - $2,786
280 Added 1.6%
17,732 $165,000
Q3 2023

Nov 13, 2023

SELL
$6.55 - $9.37 $8,266 - $11,824
-1,262 Reduced 6.74%
17,452 $114,000
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $9,666 - $11,989
1,262 Added 7.23%
18,714 $152,000
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $16,640 - $23,500
2,000 Added 12.94%
17,452 $149,000
Q4 2022

Feb 10, 2023

BUY
$7.65 - $14.43 $15,300 - $28,860
2,000 Added 14.87%
15,452 $143,000
Q3 2022

Nov 10, 2022

BUY
$8.9 - $12.86 $53,400 - $77,160
6,000 Added 80.52%
13,452 $138,000
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $33,026 - $58,011
4,518 Added 153.99%
7,452 $74,000
Q1 2022

May 12, 2022

BUY
$9.74 - $17.69 $4,694 - $8,526
482 Added 19.66%
2,934 $36,000
Q4 2021

Feb 11, 2022

BUY
$16.88 - $23.31 $7,629 - $10,536
452 Added 22.6%
2,452 $42,000
Q2 2021

Aug 06, 2021

BUY
$10.16 - $28.86 $20,320 - $57,720
2,000 New
2,000 $45,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.